Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Objectives

To evaluate whether remdesivir is associated with cardiac adverse events (CAEs), addressing concerns raised by basic experiments, clinical case reports and observational studies.

Design

Systematic review and meta-analysis.

Data sources

MEDLINE and Embase, searched from January 2020 to December 2023.

Study selection

Randomised controlled trials (RCTs) comparing remdesivir with placebo or standard care in patients with COVID-19, with a primary focus on cardiac safety.

Eligibility criteria for selecting studies

We included RCTs that evaluated the safety of remdesivir in patients with COVID-19 . Eligible studies were those that compared remdesivir with placebo or standard care in adult patientsCOVID-19 . Inclusion criteria emphasised safety outcom

SUBMITTER: Yang C 

PROVIDER: S-EPMC12273096 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature